Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2020 on Friday, May 8, 2020 before the opening of the U.S. financial markets. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements.
NEW YORK (AP) — Axsome Therapeutics Inc. (AXSM) on Friday reported a loss of $32.5 million in its first quarter.
The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?
Key details in an antidepressant's clinical trial may signal a revolutionary therapy for patients.
Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint) Demonstrated rapid.
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauc…
As the month of May kicked off, stocks got off to a rocky start. The market slumped in response to a first quarter profit miss from eCommerce giant Amazon (NASDAQ:AMZN) and its plan to put all second-quarter earnings towards its COVID-19 response, with all th…
Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond.
As there is currently no FDA-approved treatment for Alzheimer’s agitation, any progress here could be lucrative. Axsome Therapeutics has announced a big step forward in its midstage Alzheimer’s study
Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...
Just what exactly is going on with this company, which has had success in nearly every single clinical trial it initiated in recent years?
Q4 2019 Axsome Therapeutics Inc Earnings Call
The past few weeks have been quite busy for Axsome Therapeutics (NASDAQ: AXSM), notching two wins and one failure in late-stage clinical trials. On March 30, the company reported its drug AXS-05 failed to achieve the primary endpoint in a phase 3 clinical trial for patients with treatment-resistant depression. Weeks later, Axsome hailed a clinical trial success with AXS-05 for Alzheimer's disease-related agitation.
Q1 2020 Axsome Therapeutics Inc Earnings Call
Shares of Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biopharmaceutical company, rocketed 61.5% in April, according to data from S&P Global Market Intelligence. March was a rough month for Axsome Therapeutics shareholders. Investors that held on to their shares were made whole by the end of April thanks to a couple of positive data drops.
AXSM earnings call for the period ending March 31, 2020.
NEW YORK, April 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, DIS, RCL, and TTD. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ide…
NEW YORK, April 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, DIS, RCL, and TTD. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ide…
One biotech has been big long-time winner, the other is a promising up-and-comer with no revenue -- yet. But picking an investment is always a bet on the future.
Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a virtual-only meeting format due to continued public health concerns resulting from the COVID-19 pandemic, government-recommended and required limits on public gatherings, and to protect the health and safety of the Company’s stockholders, directors, and employees. Stockholders will not be able to attend the Annual Meeting in person. The Company’s stockholders as of the close of business on April 9, 2020 (the “Record Date”) can join the live virtual meeting.
Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe.
Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
Axsome Therapeutics is seeking two NDA filings this year for MDD and migraine.A go-ahead by the FDA could unveil a peak sales opportunity worth billions of dollars next year.Highlighted by the recent slide in the share price, even a fraction of the market imp…
Axsome's Alzheimer's agitation drug AXS-05 met its primary endpoint.TRACON reports positive data from its cancer trial.Syndax has an update on its leukemia drug candidate.
During today's call, we will be making certain forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date, and the company disclaims any obligation to update such statements.
Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.
Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further.